The increase of anti-inflammatory cytokines (such as TGF-β and IL-10) and TH 1-opposing TH 2 cytokines (such as IL-13) during CARS is useful to counteract the proinflammatory responses of SIRS. The gene discussed is IL13; the disease is systemic inflammatory response syndrome.